Fredun Pharmaceuticals Ltd
BSE:539730
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
645.1
1 945.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Fredun Pharmaceuticals Ltd
BSE:539730
|
7B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
530.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
278.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.8B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
222.3B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.6B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.1B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.2B EUR |
Loading...
|
Market Distribution
| Min | -153 833.3% |
| 30th Percentile | 2.7% |
| Median | 7.3% |
| 70th Percentile | 13.2% |
| Max | 9 977% |
Other Profitability Ratios
Fredun Pharmaceuticals Ltd
Glance View
Fredun Pharmaceuticals Ltd. engages in the manufacture and sale of pharmaceuticals, neutraceuticals, herbal and dietary supplements. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2016-03-17. The firm is primarily engaged in the business of pharmaceuticals and healthcare. The company operates through pharmaceutical formulation segment. The company offers a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. The company is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The firm primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Fredun Pharmaceuticals Ltd is 10.8%, which is above its 3-year median of 9.9%.
Over the last 3 years, Fredun Pharmaceuticals Ltd’s Operating Margin has increased from 6% to 10.8%. During this period, it reached a low of 6% on Jun 30, 2022 and a high of 10.9% on Dec 31, 2023.